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Introduction 
  
 
 
INTRODUCTION 
Coronary  artery disease is the most common cause of mortality in 
type 2 diabetes mellitus. Type 2 diabetes is also increasing in epidemic 
proportions in south Indian population.Despite the development of modern 
coronary care unit, acute myocardial infarction diabetes mellitus is still 
challenge to physicians because of atypical presentation of AMI in diabetes, 
too many variables predicting the outcome of treatment. 
Acute Myocardial Infarction is the leading cause of mortality in both 
developed and developing countries (Rogers WJ et.al
1
., Kesteloot H et.al
2
). 
Factors contributing to death in diabetics following Acute Myocardial 
Infarction are many. 
These factors relate mainly to electrical disturbances in the form of 
Arrhythmia (Carmeliet E
3
, Thompson CA
4
) and mechanical disturbances in 
the form of pump failure ( Hochman et. al
5.
, Bertrand M et. al
6
.). Most 
sudden deaths in Acute Myocardial Infarction occur within one hour due to 
ventricular fibrillation and also due to left ventricular failure when there is an 
extensive injury ( Lewis EF et. Al
7
.) Rest of the deaths following Myocardial 
Infarction occur within first one week and death cannot be predicted and 
occurs suddenly. Hence many trials have been conducted to identify markers 
that would be helpful to predict the risk of such adverse cardiac events. 
 
 
Many trials have used serum Magnesium level (Milionis HJet.al
8
.,) C-
Reactive Protein levels (Ridker PM, Morrow DA et.al
9
.,) 
Malonyldialdehyde, (Pol Merkuriusz Lek
10
) white blood cell count 
(Comparan Nunez. A et. Al 
10.
,) as a predictor for mortality and morbidity 
following  Acute Myocardial Infarction and risk of developing adverse 
cardiac events like sudden cardiac death and congestive heart failure. This 
Study Is One Of Such Kind In That It Tries To VALIDATE THE 
PROGNOSTIC ROLE OF METABOLIC FACTORS (SERUM URIC 
ACID LEVEL,BLOOD SUGAR ,TOTAL CHOLESTEROL LEVELS) 
FOLLOWING ACUTE MYOCARDIAL INFARCTION IN TYPE 2 
DIABETES(Kojima S., Sakamoto, Am .J Cardiol . 2005 Aug, Sakai H 
University of Medical Science, Otsu, Japan, Niizeki T., J. Cardiology 2006 
May, Joshua M,Circulation 2003: American Heart Association.) 
Previous studies have established that serum uric acid levels reflect 
circulating xanthine oxidase activity and oxidative stress production 
following Acute Myocardial Infarction.  Free radicals produced in large 
amounts during myocardial ischemia and reperfusion take part in the 
degradation of cellular and  subcellular membrane structures. The source of 
oxygen radicals in ischemic myocardium are Neutrophils recruited into the 
necrotic region as well as metabolic transformation of Hypoxanthine and 
Xanthine to Uric acid (Domonsky L et. al
10.
) 
 
 
Thus it is evident that elevated Uric acid levels is a good marker of 
oxidative stress and useful to assess the prognostic events in AMI. This 
forms the basis of the study. 
Hyperglycemia on admission is a well known predictor of mortality 
after myocardial infarction even among without known  type 2 diabetes 
mellitus as evidenced by journal of American college of cardiology (J Am 
Coll Cardiol, 2002; 40:1748-1754 ). 
10
 This study is one to validate 
prognostic role of uric acid along with blood sugar & total cholesterol after 
myocardial infarction in type 2 diabetes mellitus. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims of the Study  
 
 
 
 
IMS OF THE STUDY 
1. To  know about serum uric acid level and impact on short term 
mortality 
2. On  admission glucose  and total cholesterol  levels and their impact 
on severity of AMI along with serum uric acid elevation 
3. To study the atypical presentations in DM  presenting with acute 
myocardial infarction 
4. To assess the prognostic significance of serum Uric acid level in 
Acute Myocardial Infarction in type 2 diabetics. 
5.  To evaluate serum Uric acid levels with incidence of cardiac failure in 
diabetes with AMI. 
6. To  validate the relation between Quantitative serum Uric acid level 
on   admission and Killip’s class status on AMI  in type2 DM, 
7. To know whether the incidence of Arrhythmias bears a relation with 
serum  Uric acid level in Acute Myocardial Infarction. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
 
 
REVIEW OF LITERATURE 
Ischemic Heart Disease in the generic designation for a spectrum of 
disorders resulting from imbalance between the myocardial need for oxygen 
and the adequacy of blood supply
11
. In 90- 95% of cases the reduction in the 
coronary blood flow is related to atherosclerotic narrowing or the 
subepicardial coronary trunks. Coronary vasospasm alone or superimposed 
on atherosclerotic narrowing may contribute to the reduction of flow 
12.
 
Depending upon the rate of development of the arterial narrowing and 
its ultimate severity, four basic clinico pathologic syndromes may result. 
They are 
1. Angina pectoris. 
2. Myocardial Infarction 
3. Chronic Ischemic Heart Disease 
4. Sudden Cardiac Death – which may be superimposed on any of the 
three  conditions. 
MYOCARDIAL INFARCTION : 
This is the catastrophic frequently fatal form of Ischemic Heart 
Disease that usually results from precipitous reduction or arrest of a 
significant portion of coronary flow. In great majority of cases wide spread 
 
 
severe coronary atherosclerosis of the coronary arteries underlie Myocardial 
Infarction. In addition some sudden event such as coronary thrombosis must 
unfavorably alter the precarious balance. Alternatively the myocardial supply 
can be suddenly reduced by a superimposed vasospasm. Congenital 
abnormalities such as anomalous origin of left anterior descending coronary 
artery from the pulmonary artery may cause myocardial ischemia and 
infarction. But it is very rare. 
Coronary atherosclerosis creates a disparity between myocardial needs 
and supply. Myocardium extracts a high and virtually fixed fraction of 
oxygen from the coronary arterial blood. Atherosclerotic arteries can not 
dilate and so incapable of adjusting to the demands. Transient deficit of 
oxygen can be compensated by anerobic glycolysis with the production of 
lactate
13
. If the imbalance is not transient, it passes from the reversible 
ischemic injury to the irreversible ischemic necrosis. Depending upon the 
rate of development of the arterial narrowing and its ultimate severity, three 
basic clinico pathologic syndromes occur namely Angina pectoris, Acute 
coronary insufficiency & Myocardial Infarction. 
Angina pectoris is a clinical syndrome resulting from transient 
reversible myocardial ischemia and is produced by any effort which 
increases the metabolic demands of the myocardium beyond the capacity of 
the coronary circulation. The anginal pain is due to accumulation of certain 
 
 
metabolites that are formed in ischemic working muscle. It is diagnosed 
clinically by the typical history of the site, the character and duration of pain, 
the site of its radiation and by its characteristic precipitating and relieving 
factors. Here the ECG will be usually normal. Ischemic changes can be 
demonstrated only by the stress ECG. 
Acute Myocardial Infarction is a pathologic process resulting  from 
the reduced perfusion of a segment of the myocardium such that irreversible 
injury occurs. The infarct may be subendocardial or transmural. 
Subendocardial infarct refers to a multifocal, non-confluent areas of 
ischemic necrosis, often distributed circumferentially. This does not extend 
beyond. The inner one third to one half of the thickness of the left ventricular 
wall. The patients with this type of infarction are more prone for cardiac 
arrhythmias. Coronary thrombosis is not found in more than 10% such 
cases
14.
 
Transmural infarct refers to a confluent area of ischemic necrosis 
extending at some point from the subendocardium to the epicardium . 
Coronary thrombosis is usually present in 90-95% of these cases. 
EPIDEMIOLOGY : 
The incidence of fatal Myocardial Infarction progressively rises with 
age to peak in the 55-65 years old group. 
 
 
Myocardial Infarction occur in younger individuals, even in the third 
decade of life, particularly when predispositions to atherosclerosis, 
Hypertension diabetes, familial hypercholesterolemia & other causes of 
hyperlipoproteinemia are present. 
Virtually throughout life, males are at significantly greater risk than 
females, the differential progressively declining with advancing age. Except 
for those having some predisposing atherogenic condition, women are 
remarkably protected against Myocardial Infarction during reproductive life. 
Women using oral contraceptives have 3 to 4 fold greater risk than non users 
and this increased risk does not appear to be related to the duration of use
15
. 
CIGARETTE SMOKING: 
Cigarette smoking particularly in combination with other risk factors 
has been shown to have a strong and consistent association with increased 
incidence of atherosclerosis, by increasing catecholamine stimulation which 
enhances platelet aggregation and peripheral lipid mobilization and 
decreasing the ratio of  HDL to LDL  
16
. 
STRESS AND PERSONALITY : 
Stress is associated with increased catecholamine secretion and  
mental stress may thus be a aggravating factor. Type A individuals who are 
 
 
anxious, aggressive, impatient, competitive, always in a frustrate mood are 
more prone for IHD
17
. 
SEDENTARY LIFE STYLE : 
Exercise conditioning when regularly employed, reduces the rate of 
fatal Heart disease
18
.It is proved that HDL level increases with exercise, & 
also augments fibrinolytic response and there by provide a 
potentialprotective mechanism against development of thrombi within 
coronary arteries
19
. 
DIABETES MELLITUS : 
It has been shown that a diabetic patients serum can cause hyperplasia 
of smooth muscle cells. Furthermore, high blood sugar is often associated 
with obesity, hypertension, increased triglycerides, Low HDL, increased 
LDL and abnormal platelet adhesiveness. Diabetes is said to double the risk 
of ischemia in men and women 3-4 times. Silent Myocardial Infarction is 
thought to occur with increased frequency in diabetes and should be 
suspected whenever symptoms of left ventricular failure appear suddenly
20
. 
CORONARY BLOOD FLOW : 
  The blood flow in coronary arteries resembles that in other regions in 
being dependant on the blood pressure and on the vascular resistance of the 
 
 
arteries and the arterioles. A feature of the coronary circulation is that the 
arteries are compressed by the contracting myocardium during systole. 
Consequently coronary blood flow occurs mainly during diastole 
21.
 
The normal coronary circulation is dominated and controlled by  the 
myocardial requirements for oxygen. This need is met by the heart’s ability 
to vary coronary vascular resistance and therefore blood flow. Considerably 
while the myocardium extracts a high and relatively fixed percentage of 
oxygen. 
The large epicardial vessels serve as conduits in healthy persons, 
although they are capable of constriction and relaxation they are referred as 
the conductance vessels. The intramyocardial vessels normally exhibit 
striking changes in tone and are therefore referred as resistance vessels. 
Hence with exercise and emotional stress, the changing oxygen needs 
affect coronary vascular resistance and in this manner regulate the supply of 
blood and oxygen (metabolic regulation). These same vessels adapt to 
physiologic alterations in blood pressure in order to maintain coronary blood 
flow at levels appropriate to myocardial needs. (Auto regulation). 
The frequencies of the critical narrowing of each of the three main 
arterial trunks and the associated myocardial lesions are as follows
22
 : 
 
 
 
 a) LEFT ANTERIOR DESCENDING : Anterior wall of left ventricle near   
           (40-50%)           coronary artery apex, anterior 2/3 septum 
  b) RIGHT CORONARY ARTERY   :     Posterior wall of left ventricle 
                  (30-40%)     Posterior 1/3 of inter  ventricular  septum 
c) LEFT CIRCUMFLEX C ARTERY :     Lateral wall of left ventricle. 
                            (15-20%) 
REVISED DEFINITION OF MYOCARDIAL INFARCTION: 
23
 
Either one of the following criteria satisfies the diagnosis for an acute, 
evolving or recent MI : 
1. Typical rise and gradual fall (troponin) or more rapid rise and fall  
(CK- MB) of biochemical markers of myocardial necrosis with at least 
one of the following : 
a. Ischemic symptorns. 
b. Development of pathologic Q waves on the ECG reading. 
c. ECG changes indicative of ischemia (ST Elevation or depression) 
d. Coronary artery intervention (eg : coronary angioplasty) 
2. Pathological findings of acute MI . 
Criteria for established MI : 
Either of the following criteria satisfies the diagnosis for  established MI : 
 
 
1. Development of new pathological Q waves on serial ECG readings. The 
patient may or may not remember previous symptoms. Biochemical 
markers of myocardial necrosis may have normalized, depending on the 
length of time that has passed since the infarct developed. 
2. Pathological findings of a healed or healing MI. 
Several researchers all over the world have been attempting for 
decades to establish those criteria that best define patients with a poorer 
prognosis. Taken in toto, the various studies and articles published in the 
literature may be classified conveniently into two major headings: 
1. Criteria obtained at the initial physician contact including patient 
characteristics (eg : age, gender), details of history, the initial clinical 
examination findings . 
2. The laboratory parameters obtained on admission. 
CHEST PAIN : 
Despite the recent advances in the laboratory diagnosis of Acute 
Myocardial Infarction (AMI), the history remains of substantial value in 
arriving at a diagnosis. A prodrome of chest discomfort can usually be 
elicited in 20 to 60% of patients with AMI. 
24
 
The pain of AMI resembles that of classic Angina pectoris, except that 
is more severe, occurs at rest or with lesser activity than usual, lasts longer 
 
 
(more than 30 minutes) is associated with more systemic symptoms (eg : 
diaphoresis, nausea) and not relieved by rest or nitrates. On occasion it 
radiates to the arms. Less common sites of radiation include the abdomen 
back, lower jaw, and neck. The pain may radiate as high as the occipital area 
but not below the umbilicus. 
In an analysis of the atypical presentations of AMI, Bean et.al., lists 
the following : 
25
 
1. Congestive Heart failure. 
2. Classic angina pectoris (not severe or prolonged). 
3. Atypical locations of the pain. 
4. CNS manifestations, from a reduced cardiac output, resembling a 
stroke. 
5. Apprehension and nervousness. 
6. Sudden Mania and Psychosis. 
7. Syncope, over whelming weakness. 
8. Acute indigestion,Peripheral embolism. 
To this list must be added those patients with “silent” AMI – who have 
had no symptoms at onset. Such presentations are commoner in diabetes and 
hypertensives, and both of these conditions are also associated with an 
increased mortality. 
26
 
 
 
PHYSICAL FINDINGS : 
Most patients are anxious and restless, attempting unsuccessfully to 
relieve the pain by moving about in bed, altering  their position, and 
stretching. Pallor associated with perspiration and coolness of the extremities 
occurs commonly. About one fourth of patients with Anterior Infarction 
have manifestations of sympathetic nervous system hyperactivity 
(tachycardia or hypertension) and upto one half with Inferior Infarction show 
evidence of para sympathetic hyperactivity (bradycardia or hypotension). 
27
 
The apical impulse may be difficult to palpate. S3, S4 gallop sounds, 
decreased intensity of first Heart sound and paradoxical splitting of second 
Heart sound may be there. A transient mid systolic or late systolic apical 
systolic murmurs may be heard in mitral area. Pericardial friction rub is 
heard at some time in the course of disease. The carotid pulse is often 
decreased in volume, reflecting reduced stroke volume. In most transmural 
MI patients, systolic pressure declines by approximately 10-15 mmHg from 
the pre infarction state. 
SERUM CARDIAC BIOMARKERS : 
These cardiac markers are released into the blood in large quantities 
from necrotic heart muscle after MI. 
 
 
Creatinine phosphokinase (CK) rises within 4 to 8 hour and generally 
returns to normal by 48 to 72 hrs . An important draw back of total CK 
measurement is its lack of specificity for STEMI (ST Elevation MI), as CK 
may be elevated with skeletal muscle trauma. Creatinine phosphokinase MB 
isoenzyme (CK-.MB) has the advantage over total CK that is not present in 
significant concentrations in extra cardiac tissue and therefore is more 
specific. 
However, cardiac surgery, myocarditis, electrical cardioversion often 
result in elevated serum levels of CK-MB. A ratio ( relative index) of CKMB 
mass : CK activity > 2.5 suggests but is not diagnostic of a myocardial rather 
than a skeletal muscle source for the CK – MB elevation. 
28
 
Cardiac specific troponin T ( cTnT) and cardiac specific troponin I 
(cTnI) are not normally detectable in the blood of healthy individuals, but 
may increase after STEMI to levels > 20 times higher than the upper 
reference limit. They are now the preferred biochemical markers of MI. 
Levels of cardiac troponins remain elevated for 7 to 1o days after STEMI . 
Myoglobin is released into the blood within a few hours of the onset 
of STEMI. But it lacks cardiac specificity, because it is rapidly excreted in 
the urine, So blood levels return to the normal range with in 24 hours of the 
onset of infarction. 
 
 
Serum lipids are often determined in patients with STEMI. During the 
first 24 to 48 hours after admission, total Cholesterol and HDL cholesterol 
remain at or near baseline values, generally fall after 48 hours. The fall in 
HDL cholesterol after STEMI is greater than total cholesterol. Elevation of 
white blood cell count (Polymorphonuclear Leukocytosis) appears within a 
few hours and peaks at 2 to 4 days. 
Erythrocyte Sedimentation Rate peaking during the first week and 
elevated for 1 or 2 weeks. Other markers like C-Reactive Protein, LDH, 
SGOT also elevated. 
29
 
CARDIAC IMAGING :   
Two dimensional echocardiography, Doppler echocardiography , 
myocardial perfusing imaging with Thallium 201 or 99mTc – Sestamibi scan 
useful in Acute MI. Radio nuclide ventriculography carried out with 99mTc 
labeled red blood cells frequently demonstrates wall motion disorders and 
ejection fraction in MI patients. 
30
 
HEMODYNAMIC ABNORMALITIES: 
In 1976, Swan, Forrester, and their associates measured the cardiac 
output and wedge pressure simultaneously in a large series of patients with 
acute Myocardial Infarction and identified four major hemodynamic subsets 
of patients.
31
 
 
 
1. Patients with normal perfusion and without pulmonary congestion 
(normal cardiac output and normal wedge pressure). 
2. Patients with normal perfusion and pulmonary congestion. (normal 
cardiac output and elevated wedge pressure). 
3. Patients with decreased perfusion but without pulmonary congestion.                  
(reduced cardiac output and normal wedge pressure). 
4. Patients with decreased perfusion and pulmonary congestion. (reduced 
cardiac output and elevated wedge pressure). 
This classification which overlaps with a crude clinical classification 
proposed earlier by Killip and Kimball, has proved to be quite useful, but it 
should be noted that patients frequently pass from one category to another 
with therapy and sometimes even spontaneously. 
HEMODYNAMIC CLASSIFICATION OF PATIENTS WITH 
AMI BY KILLIP CLASSIFICATION : 
CLASS DEFINITION
31
 
I  Patients with MI and no evidence of Heart failure. 
II Patients with MI, Early Heart failure as manifested by bibasilar 
rales, and at times S3 gallop. 
III Patients with MI, features of pulmonary edema (Rales >1/2lung 
fields) 
IV Patients with MI, cardiogenic shock 
 
 
 
HEART FAILURE : 
Heart failure is a state when the heart cannot maintain an adequate 
cardiac output or can do so only at the expense of an elevated filling 
pressure. Heart failure is frequently due to coronary artery disease, tends to 
affect elderly people and often leads to prolonged disability.Cardiac output is 
a function of preload, afterload and myocardial contractility. The primary 
abnormality in Heart failure is impairment of ventricular function leading to 
a fall in cardiac output. This activates counter regulatory neurohormonal 
mechanisms that in normal physiological circumstances would support 
cardiac function, but in the setting of impaired ventricular function can lead 
to a deleterious increase in both afterload and preload. A vicious circle may 
be established because any additional fall in cardiac output will cause further 
neurohormonal activation and increasing peripheral vascular resistance. 
33
 
Stimulation of the renin-angiotensin-aldosterone system leads to 
vasoconstriction, salt and water retention and sympathetic activation 
mediated by angiotensin II, which is a potent constrictor of arterioles both in 
the kidney and systemic circulation. Salt and water retention is promoted by 
release of aldosterone, endothelin (a potent vasoconstrictor peptide with 
marked effects on the renal vasculature)and in severe Heart failure. Anti 
Diuretic Hormone (ADH), Natriuretic peptides are released from the atria in 
response to atrial stretch, and act as physiological antagonists to the fluid 
 
 
conserving effect of aldosterone and extremely useful in diagnosis,prognosis  
&monitoring therapy. 
After Myocardial Infarction, cardiac contractility is impaired and 
neurohormonal activation may lead to hypertrophy of non–infarcted 
segments with thinning, dilatation and expansion of the infarcted segment. 
(remodelling ). This may lead to deterioration in ventricular function and 
worsening  of heart failure. 
MECHANISMS OF CHRONIC CONGESTIVE HEART FAILURE 
DUE TO CORONARY ARTERY DISEASE: 
35
  
(Severely depressed LV function) : 
MYOCARDIAL INFARCTION : 
1. Large (usually Anterior) transmural infarct with severe depression of 
LV function (EF<30-35%) due to acute extensive loss of myocardium. 
2. Multiple infarcts with extensive myocardial fibrosis (not always 
clinically recognized) resulting in severe reduction in systolic function 
(Ischemic cardiomyopathy) 
3. Prior myocardial infarction with mitral regurgitation (systolicfunction 
mildly to severely decreased). 
4. LV aneurysm. 
5. Late post MI systolic dysfunction, known as LV remodelling. 
 
 
MYOCARDIAL ISCHEMIA : 
1. Extensive regions of hibernating LV myocardium – viable but  
ischemic (low coronary blood flow) zones of LV systolic dysfunction 
often accompanied by reversible and irreversible dysfunction fibrosis 
or scar. 
2. Ischemic papillary muscle dysfunction resulting in mitral 
regurgitation. 
NORMAL OR MILDLY DEPRESSED LV FUNCTION: 
1. Diastolic dysfunction related to ischemia and or LV hypertrophy. 
2. Severe mitral regurgitation. 
3. Ventricular septal defect (rare) 
Any of above superimposed on cardiac distress related to other 
etiologies    
1. Valvular heart disease 
2. Preexisting non ischemic cardiomyopathy. 
MORTALITY : 
               Studies involving large number of patients have revealed wide 
variations in the time elapsed between symptom onset and arrival at the 
hospital. Researchers have investigated for a relationship between this delay 
and in hospital mortality. However there are certain complexities in their 
relationship as follows . 
 
 
Most sudden deaths in AMI occur due to ventricular Arrhythmias and 
this risk is maximum in the first hour after symptom onset. With each 
subsequent hour, the risk decreases, giving rise to the paradoxical situation 
where a patient who presents late to the hospital has a lesser risk of sudden 
death than one who presents early for treatment. 40-60% of patients have 
some degree of left ventricular dysfunction at presentation if untreated, this 
may go on to a cardiogenic shock, the commonest cause of inhospital death 
in AMI. This implies that the patient who presents sufficiently early for 
shock to be treated or prevented has a better prognosis . 
Established beyond reasonable doubt that the patient who presents 
early enough for thrombolysis has large benefits from reperfusion, vastly 
improving the prognosis. 
Raitt et.al., have shown that each 30 minute delay is associated with a 
1% increase infarct size.
36
 Julian D.G analyzing the results of five mortality 
trials, concluded that gaining about one hour prior to thrombolysis decreases 
mortality by about 17%.
37
 Even for patients presenting at later than this 
window period of 6 hours, thrombolysis can be beneficial, compared to those 
that do not receive such treatment. Yusuf et al., showed a 22% reduction in 
mortality for those treated at 12-24 hours. The ISIS – 2 trial extended the 
concept of beneficial late perfusion with its results revealing a significant 
benefit beyond 6-12 hours, and even 12-24 hours.
38
 These findings are 
 
 
confirmed by the ISIS- 3 and EMERAS trials. 
39 
The newer agents such as t–
PA, Urokinase or even emergency coronary angioplasty may achieve better 
late reperfusion than Streptokinase. 
40
 
GENDER RELATED DIFFERENCES IN  PROGNOSIS  : 
Unlike in previous years, the incidence of AMI in women is 
increasing. AMI in women has certain peculiarities. Women are mostly older 
than men at presentation and are more likely to have atypical pain, 
Hypertension, Diabetes, unstable angina, hyperlipidemia, congestive cardiac 
failure or silent infarctions are all commoner in women. Women more 
frequently have non – Q AMI and tend to present later to hospital. 
41
 Of 
interest after STEMI, younger women but not older women have higher rates 
of inhospital mortality than men of the same age. 
The pathogenic mechanisms different in women include : 
42
 
 A greater incidence of vasospastic and micro circulatory angina. 
 Different plaque components (more cellular and fibrous tissue). 
 Different endothelial tone due to hormonal influences. 
 Different hemostasis (higher fibrinogen and factor VIII levels). 
 
 
 
DIABETES AND ITS EFFECTS ON PROGNOSIS : 
The early pioneering studies an AMI, especially those by killip and 
Norris suggested that the presence of diabetes had a significant effect on the 
mortality. The famous Framingham Heart study indicated that diabetes 
increased the risk of death in women, but not men, after a first AMI. They 
tend to have larger infarcts, and show a greater incidence of shock, cardiac 
failure and metabolic problems.
43
 
HYPERTENSION AND ITS EFFECT ON  PROGNOSIS : 
The GISSI – 2 trial one of the largest ever series of AMI patients 
(11,843 patients, of which 3306 were hypertensive) investigated the 
prognostic value of hypertension in those receiving thrombolysis. Their 
results show a significantly higher mortality for hypertensives LV failure and 
recurrent ischemic events were also more common among hypertensives. 
44
 
Patients develop cardiogenic shock when more than 40% of the 
myocardium is destroyed. Beyond the immediate phase, cardiogenic shock is 
the commonest cause of mortality. The hospital mortality for cardiogenic 
shock is in the region of 60-80%. The incidence of ventricular arrhythmias 
and heart block was found to be higher in these patients. (Killip et.al.,) By 
multivariate analysis of their cohort of 845 patients. Hands et.al., found that 
the predictors of cardiogenic shock included age >65, ejection fraction 
 
 
<35%, peak CK-MB value more than 160 IU/ L and a history of diabetes or 
prior infarction
. 45
 
PROGNOSTIC PARAMETERS AT HOSPITAL ADMISSION IN AMI
46 
 
  
PARAMETERS EFFECT ON PROGNOSIS 
 Age Prognosis worsens with increasing age 
Sex Women have a worse prognosis than men 
Heart Rate Heart rate >100/mt indicates a poor prognosis 
Cardiogenic shock A very high early mortality 
Congestive Heart failure Indicates a poor prognosis even when treated 
successfully 
ST segment deviation The more ST segment deviation or Q wave 
formation, the larger the infarct and the worse 
prognosis. 
Enzymes Not admission levels, but evolving rise in 
cardiac enzymes estimate infarct size 
Troponin levels Elevated admission troponin – I or 
troponin – T indicates a worse prognosis even 
in the absence of rising CPK or CK MB. 
 
 
URIC ACID BIOCHEMISTRY 
  Uric acid is the final breakdown product of Purine metabolism. Most 
mammals have the ability to catabolize purines to allantoin, a more water 
soluble end product. 
 Purines such as adenosine and guanine from the breakdown of  
ingested nucleic acids or from tissue destruction are converted into uric acid 
primarily in the liver. Uric acid is transported in the plasma from the liver to 
the kidney, where it is filtered by the glomerulus. Reabsorption of 98-100% 
of the uric acid in the glomerular filtrate occurs in the proximal tubules. 
Small amounts of uric acid are secreted by the distal tubules into the urine. 
This route accounts for about 70% of the daily uric acid excretion. The 
remainder is excreted into the GI tract and degraded by bacterial enzymes. 
Uric acid is produced only in tissues that contain xanthine oxidase, primarily 
the liver and small intestine. 
Nearly all of the uric acid in plasma is present as monosodium urate. 
At the pH of plasma, Urate is insoluble; at concentrations greater than 6.4 
mg/dl the plasma is saturated. As a result, urate crystals may form and 
precipitate in the tissue. In the urine at pH<5.7, uric acid crystals may form. 
  
 
 
HUMANS CATABOLIZE PURINES TO URIC ACID : 
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Humans convert the major purine nucleosides adenosine and 
guanosine to the excreted end product uric acid via the intermediates and 
reactions. Adenosine is first deaminated to inosine by adenosinedeaminase. 
Phosphorolysis of the N-glycosidic bonds of inosine and guanosine, 
catalyzed by purine nucleoside phosphorylase releases ribose 1 – phosphate 
and a purine base. Hypoxanthine and guanine next form xanthine in 
reactions catalysed by xanthine to uric acid in a second reaction catalyzed by 
xanthine oxidase and guanase respectively. Xanthine is then oxidised to uric 
acid in a second reaction catalyzed by xanthine oxidase. Thus xanthine 
oxidase provides a potential locus for pharmacologic intervention in patients 
with hyperuricemia. 
Net excretion of total uric acid in normal humans averages 400- 600 
mg/24hr. In mammals other than higher primates, the enzyme uricase 
cleaves uric acid, forming the highly water soluble end product allantion. 
However, since humans lack uricase, the end product of purine catabolism in 
man is uric acid. Amphibians, birds and reptiles also lack uricase and excrete 
uric acid and guanine as end products of purine catabolism. 
Humans catabolize purines to weak uric acid. (pk 5.8) which 
depending on urinary pH, exists as the relatively insoluble acid (at acidic 
 
 
pH) or its more soluble sodium urate salt. Urate crystals are diagnosic of 
gout, a metabolic disorder of purine catabolism. Other disorders include 
Lesch – Nyhan syndrome, von Gierkes disease and hypouricemias. 
HYPERURICEMIA : 
It can result from increased production or decreased excretion of uric 
acid or from a combination of the two processes. Hyperuricemia is defined 
as a plasma concentration of > 7mg/dl in males and  > 6mg/dl in females. 
CLASSIFICATION OF HYPERURICEMIA BY PATHOPHYSIOLOGY48 
URATE OVERPRODUCTION : 
 Primary idiopathic HPRT deficiency, PRPP synthetase Over activity 
  Hemolytic processes, Lymphoproliferative Diseases 
  Myeloproliferative Diseases, Rhabdomyolysis,Exercise 
  Alcohol, Obesity, Purine rich diet, Polycythemia vera 
  Psoariasis, Pagets disease 
DECREASED URIC ACID EXCRETION: 
  Lead intoxication, Renal insufficiency,Hyperparathyroidism 
  Polycystic kidney disease,Hypothyroidism 
  Diabetes insipidus, Toxaemia of pregnancy 
  Hypertension, Bartters syndrome 
 
 
  Acidosis,Down syndrome, Drug ingestion 
  Salicylates (>2g/d), Starvation ketosis, Diuretics 
  Berylliosis ,Alcohol 
  Sarcoidosis, Levodopa,Ethambutol,Pyrazinamide,Cyclosporine 
COMBINED MECHANISM : 
 Glucose - 6 – Phosphatase deficiency 
 Fructose – 1 – Phosphate aldolase deficiency 
 Alcohol, Shock 
Note : HPRT : Hypoxanthine Phospho Ribosyl Transferase 
PRPP : Phospho Ribosyl Pyro Phosphate.  
Accelerated purine nucleotide degradation can also cause 
hyperuricemia i.e with conditions of rapid cell turnover, proliferation or cell 
death, as in Leukemic blast crisis, cytotoxic therapy for malignancy, 
hemolysis or rhabdomyolysis. Hyperuricemia can result from excessive 
degradation of muscle ATP after strenuous physical exercise or status 
epilepticus. 
Hyperuricemia of Myocardial Infarction, smoke inhalation and acute 
respiratory failure may also be related to accelerated breakdown of ATP. 
 
 
 
SECONDARY CAUSES OF HYPERURICEMIA
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1. Obesity 
2. Dyslipidemia (Usually type 4) with raised VLDL and normal 
cholesterol levels; hypercholesterolemia with increased LDL 
cholesterol and Low HDL cholesterol. 
3. Hypertension 
4. Insulin resistence with hyperinsulinemia and impaired glucose 
tolerance. 
5. Ischemic Heart Disease. 
OXIDATIVE STRESS : 
There is evidence that oxidative stress is increased both systemically 
and in the myocardium of patients with Heart failure.
50
 Increased oxidative 
stress may be due to reduced antioxidant capacity of the increased 
production of reactive oxygen species, which may be a consequences of 
mechanical strain on the myocardium or stimulation by neuro hormones and 
inflammatory cytokines. Possible sources of increased production of reactive 
oxygen species include the mitochondria, xanthine oxidase and NADPH 
oxidase.
51
 Reactive oxygen species can stimulate myocyte hypertrophy, 
reexpression of fetal gene programs and apoptosis in cardiac myocytes in 
culture.
52 
There is no evidence that uric acid is toxic to myocardium. 
 
 
Hyperuricemia may be a marker of coincident cardiac disease, but not 
a causal risk factor. The increased plasma uric acid concentration observed 
in patients with ischemic heart disease could arise from upregulated vascular 
adenosine synthesis associated with ischemia and the subsequent degradation 
of adenosine to uric acid. The relationship of urate to endothelial function is 
complex. Plasma uric acid accounts for 60% of the free radical scavenging 
activity in human plasma. It interacts with peroxynitrite to form a stable 
Nitric oxide donar, so promoting vasodilation and reducing the potential for 
peroxynitrite induced oxidative damage. Conversely it could have an adverse 
effect on endothelial function by promotin g leukocyte adhesion to the 
endothelium.
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URIC ACID PREDICTS  CLINICAL OUTCOMES IN HEART FAILURE :  
Insights Regarding the Role of Xanthine Oxidase and Uric Acid in 
Disease Pathophysiology : 
In the current issue of circulation, Anker and Colleagues
54
 report that 
elevated levels of uric acid predict mortality and the need for heart 
transplantation in patients with congestive heart failure. Serum 
concentrations of uric acid added important prognostic information alone 
and when combined with measures of cardiac function (ejectionfraction) and 
patient functional status (maximal oxygen consumption with exercise) and 
 
 
were independent of renal function, serum sodium, Blood urea, diuretic 
usage, and patient age. 
A consideration of the mechanism of uric acid production and 
metabolism offers insight into the relationship between uric acid levels and 
Heart failure outcomes. Moreover, uric acid levels may reflect xanthine 
oxidase pathway activity, which has the potential to myocardial energetics 
and myofilament calcium sensitivity. 
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POTENTIAL MECHANISMS FOR INCREASED URIC ACID IN 
HEART FAILURE : 
Uric acid is a metabolic byproduct of purine metabolism. Serum uric 
acid may increase in the failing circulation because of increased generation, 
decreased excretion, or a combination of the 2 factors. There are several 
possible contributors to increased uric acid production in Heart failure, 
including increased abundance and activity of xanthine oxidase, increased 
conversion of xanthine dehydrogenase to xanthine oxidase, or increased 
xanthine oxidase substrate resulting from enhanced ATP breakdown to 
adenosine and hypoxanthine. As uric acid is excreted primarily by the 
kidney, decreased renal perfusion could lead to increased uric acid levels. To 
the extent that Heart failure leads to tissue ischemia and a rise in serum 
lactate, renal uric acid excretion can be further impaired as lactate competes 
with urate via an organic anion exchanger in the proximal tubule. 
56
 
 
 
PATHOPHYSIOLOGICAL ROLE OF THE XANTHINE OXIDASE 
PATHWAY IN HEART FAILURE: 
  The elevation in serum uric acid may reflect increased xanthine 
oxidase pathway activity and in turn the generation of superoxide and 
resultant oxidative stress via the xanthine oxidase system. 
57 
Xanthine 
oxidase is upregulated within the heart in both experimental and human heart 
failure. Much had previously been made of the difficulty in identifying 
xanthine oxidase within the hearts of certain mammalian species, including 
humans
,58
 nevertheless, it is clear that xanthine oxidase, which is produced 
in highest abundance in the liver and gut may circulate in the blood and 
adhere to endothelium in distant sites. 
Moreover, xanthine oxidase is expressed in cardiac myocytes, as 
shown by immunohistochemistry and may participate in intracrine signaling. 
PATHOPHYSIOLOGICAL ROLE OF URIC ACID IN HEART 
FAILURE : 
Beyond xanthine oxidase activity, recent experimental studies suggest 
that uric acid itself may have a role in cardiovascular and renal 
pathophysiology. This might seem surprising, as uric acid can function as an 
antioxidant both by itself and by promoting superoxide dismutase activity,
59 
and might therefore be considered potentially protective. However, uric acid 
 
 
potently stimulates vascular smooth muscle cell proliferation in vitro, an 
effect mediated by stimulation of mitogen-activated protein kinases, 
cyclooxygenase2, and platelet derived growth factor
. 60 
CLINICAL UTILITY OF URIC ACID MEASUREMENTS : 
From a clinical perspective, the current study raises the issue of 
whether serum uric acid levels should be routinely measured in Heartfailure 
patients. 
61
 Indeed this is likely to be a controversial issue, and one which 
will require evaluation in the context of measurement of brain natriuretic 
peptide (BNP), a serum marker that also possesses prognostic and diagnostic 
value in Heart failure patients. Much in the same way as BNP has been 
evaluated, it will be of great value to assess whether uric acid levels change 
in response to Heart failure therapy in a manner that predicts clinical 
outcome.  
Whether or not uric acid levels are ready for clinical use, the 
observation that uric acid levels possess prognostic information adds an 
extremely intriguing finding to mounting evidence that xanthine oxidase and 
uric acid play pathophysiological roles in Heart failure and its precursor, 
hypertension. Indeed, the amassing data have led to the planning of a clinical 
trial entitled A phase II – III prospective, Randomized, Double – Blind, 
Placebo – Controlled Efficacy and safety study of Oxypurinol Added to 
 
 
Standard therapy in patients with NYHA class III- IV Congestive Heart 
Failure (OPT-CHF) initiated in 2003, which will test clinical outcomes using 
a composite endpoint comprising measures of heart failure 
morbidity,exercise capacity, and mortality.The findings of Anker and 
colleagues, therefore, not only bring to light a potentially new diagnostic test 
but also provide a novel line of evidence that the xanthine oxidase pathway 
and / or uric acid itself may be of pathophysiological importance in heart 
failure progression 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
  
 
 
MATERIALS AND METHODS 
The study was conducted at Coimbatore medical college hospital, 
Coimbatore during  the period of  AUGUST 2008 – JULY 2010. 
100 known type 2 diabetics on treatment who were  presenting with 
AMI were included in the study and serially followed up in the intensive 
care units.Out of 100 patients 54 were males, 46 were female diabetics.  
STUDY DESIGN 
This is a prospective study design, This study is aimed to assess the 
prognostic role of metabolic factors  serum uric acid,total cholesterol & 
blood sugar levels  following Acute Myocardial Infarction in type 2 DM & 
correlating their levels with short term complications. 
This study included 100 known type 2 diabetics on medications 
presented with Acute myocardial  infarction. This study included 100 type 2 
DM patients of Acute Myocardial Infarction of which patient who had a 
normal Uric acid level were taken as a control and the rest who had elevated 
Uric acid level were taken up as study population. 
In both groups the complications and short term outcome were 
compared. 
 
 
 
INCLUSION CRITERIA : 
Patients with previous history of type 2 diabetes with Acute ST 
ELEVATION Myocardial  Infarction were entered into the study. A definite 
diagnosis of Acute ST Elevation Myocardial Infarction was made if the 
patients satisfied the following criteria: 
1. A History of typical retrosternal compressive chest pain or atypical 
presentations in type 2 diabetes lasting for more than 30 minutes, not 
relieved by rest or nitrates. 
2. Atypical symptoms, 
3. Typical ECG changes of Acute ST Elevation Myocardial Infarction 
(ST,T  changes in two contiguous leads) 
EXCLUSION CRITERIA : 
1. Patients with elevated renal parameters. 
2. Patients with Gout. 
3. Patients with History of chronic alcoholism. 
4. Patients with previous History of IHD  & on Aspirin therapy. 
5. Patients with newly diagnosed Diabetes mellitus. 
6. Patients with hypertension and patients on Diuretics therapy. 
7. Patients with  hematological malignancy, hypothyroidism. 
 
 
Above patients were excluded because the coexisting disease or drug 
therapy might itself produce a high Uric acid level. 
Only patients known to have type 2 diabetes on any one of three 
therapies  namely diet, OHAs or insulin were included. 
 VARIABLES RECORDED DURING THE STUDY: 
Routine History, physical examination, Routine laboratory 
investigations were performed in all subjects. 
1. Presenting History : 
 Duration of chest discomfort 
 Associated symptoms like sweating, palpitations,dyspnoea. 
 Time of onset of symptoms. 
 Atypical  symptoms, 
2. Killip’s classification on admission : 
3. Admission Electrocardiogram (ECG) : 
 Site of infarction : Anterior,Extensive anterior, Inferior, Right 
     ventricular, multiple wall MI 
 No of leads with Q waves or ST Elevation. 
4. Laboratory Investigations : 
 Full Blood count 
 
 
 Blood Sugar, Blood Urea, Serum creatinine, Serum 
 Electrolytes. 
 Serum Uric acid level on admission. 
 Urine Albumin, Sugar, Deposits. 
 Serum cholesterol on admission 
Qualifying patients received thrombolytic therapy with 1.5 million 
units of Streptokinase followed by Heparin for 5 – 7 days. 
Assessment of left ventricular ejection fraction by Echocardiography 
was performed either on day 4 or 5 of hospitalisation in most patients or 
earlier if clinically indicated. 
Immediately after admission blood samples are sent for estimation of 
serum uric acid,blood sugar and total cholesterol. 
 Abnormal values were interpreated as follows : 
 1. HYPERURICEMIA  
               Males        > 7 mgs % 
               Females    > 6   mgs % 
2. HYPERGLYCEMIA : Blood sugar  > 200 mgs % 
3. DYSLIPIDEMIA : Total cholesterol  > 240 mgs % 
 
 
URIC ACID ESTIMATION : 
The method used for analysis is Enzymatic method (Uricase method) 
by using Auto analyser. In our laboratory, values taken as normal range
62
 
For Males :       3.4 - 7.0 mg/dl 
For Females :   2.4 - 6.0 mg/dl 
METHODOLOGY: 
Methods using URICASE, the enzyme that catalyzes the oxidation of 
uric acid to allantoin are most specific.
63
 The simplest of these methods 
measures the differential absorption of uric acid and allantoin at 293 nm. 
64
 
The difference in absorbance before and after incubation with URICASE is 
proportional to the uric acid concentration. 
This method has been proposed as candidate reference method.
65 
This 
method was done in our study. This is the most specific method. 
 
                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations and Results  
  
RESULTS AND OBSERVATIONS
The study population consisted of 100 type 2 diabetic patients with 54 
males and 46  females. 
days cared in adjoining immediate cardiac care ward and discharged after an 
average period of 10 days provided there were no complications.
The   various  observations made in this study are depicted  below,
 
AGE  INCIDENCE  
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No of cases 12 
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CONTROL AND STUDY POPULATION 
TABLE : 3 
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STATISTICAL  SIGNIFICANCE :   
TABLE  :  5 
 
By using unpaired ‘t’ test, the estimated   
‘t’  value = 17.2   
Degree of freedom (df ) = 98  
Standard Error  of difference  = 0.172 
 
The two-tailed P VALUE is less than 0.0001, this difference is considered 
to be EXTREMELY  STATISTICALLY  SIGNIFICANT.  
 
KILLIP CLASS IN HIGH SERUM URIC ACID POPULATION 
(STUDY GROUP)   
TABLE : 6 
 
URIC ACID 
VALUES 
NO OF 
CASES 
MEAN URIC 
ACID VALUE 
STANDARD 
DEVIATION 
P VALUE 
(UNPAIRED 
‘t’  TEST ) 
HIGH 
(STUDY) 
56 8.05 0.712 
< 0.0001 
NORMAL 
(CONTROL) 
44 5.09 1.005 
Killip Class I & II III & IV 
No of patients 20 36 
 Percentage of patients with
Percentage of patients with
acid population 
KILLIP CLASS IN CASES WITH CONCURRENT ELEVATION OF 
URIC ACID, TOTAL CHOLESTEROL AND BLOOD SUGAR.
 
TOTAL NO OF PATIENTS WITH CONCURRENT HYPERURICEMIA, 
HYPERGLYCEMIA & DYSLIPIDEMIA IN THIS STUDY  :  36
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INCIDENCE OF HEART FAILURE IN TOTAL POPULATION
(TABLE : 11
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PROPORTION OF HEART FAILURE CONTRIBUTED BY 
PATIENTS WITH NORMAL & HIGH SERUM URIC ACID LEVEL 
(TABLE : 13 & FIGURE 11 )
 
 
Total no of Heart
failure patients
44 
HEART FAILURE 
44 
 
 
RE 10 ) 
FIGURE  10 
 
 
59%
41%
HEART FAILURE
MALES FEMALES
 
 
MALES FEMALES
26 (59.09 %) 18 (40.90
HYPERURICEMIA NORMOUR
36 
 
 
 
%) 
ICEMIA 
8 
Contribution of patients with
Contribution of patients with
It is observed that patients with high uric acid level contributes
total incidence of Heart failure.
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HEART FAILURE IN HYPERURI
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ECHOCARDIOGRAM ANALYSIS 
TABLE : 18 
Echo findings 
Normal LV systolic function
Mild LV dysfunction 
Moderate LV dysfunction
Severe LV dysfunction 
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INCIDENCE OF ARRHYTHMIAS (IN TOTAL POPULATION) 
TABLE : 19 & FIGURE 17
Total no of patients studied
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ARRHYTHMIAS 
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PROPORTION OF ARRHYTHMIAS CONTRIBUTED BY 
PATIENTS WITH  NORMAL & HIGH SERUM URIC ACID LEVEL
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INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH HIGH 
SERUM URIC ACID LEVEL (STUDY GROUP)
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ie.  16 % of patients with high uric acid level developed   Arrhythmias.
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PROPORTION OF MORTALITY CONTRIBUTED BY PATIENTS 
WITH NORMAL & HIGH SERUM URIC ACID LEVEL Table : 26
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INCIDENCE OF MORTALITY IN PATIENTS WITH HIGH SERUM 
URIC ACID LEVEL (STUDY GROUP) 
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56 
 
 High serum uric acid level to Mortality
12 100
80%
15
= =
x
 
 Normal serum uric acid level to Mortality 
3 100
20%
15
= =
x
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MORTALITY IN AGE GROUP TABLE  28
Age 
31-40 
41-50 
51-60 
61-70 
>70 
 
 
 
0
1
2
3
4
5
6
7
31-40 41
 
 
Total No of Patients 
2 
1 
7 
 3 
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PATIENTS 
TABLE 29 
SL NO 
DISTRIBTION OF 
SYMPTOMS
1 TYPICAL CHEST PAIN
2 ATYPICAL SYMPTOMS
 
 
54%
ATYPICAL PRESENTATION
ANGINA ATYPICAL SYMPTOMS (LVF,DKA,VOMITING,CVA )
 
PRESENTATION ON ADMISSION  
 
NO OF CASES PERCENTAGE
 46 
 54 
FIGURE  27 
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Discussion 
  
 
 
DISCUSSION 
Total number of type 2 Diabetic patients included in this study were 
100, out of 100 patients  56 cases had elevated uric acid, 36  had concurrent 
elevation  of serum uric acid, blood sugar, and total cholesterol above  
normal range following myocardial infarction. 
AGE : 
Of  the 100 patients  studied 12 patients were in the age group  of 21-
30 years,32 patients were in the age group of 41- 50 years,40  patients were 
in the age group of 51- 60 years,13 patients were in the age group of 61- 70 
years,3 patients were more than  70 years of old (Table 1 &figure 1) 
SEX :  
In this study no of male patients were 54  patients, no of female  
patients were 46 (table 2 & figure 2) 
CONTROL & STUDY POPULATION: 
Out of 100 patients studied 44 patients had Normal uric acid level and 
they were taken up as control. Of which 30  (68.2 %) were males  and 14  
(31.8%) were females The rest 56  patients had elevated uric acid  level and 
they were taken up as study group. Of which  24 (42.8%) were males and 32 
(57.2 %) were females . (Table 3 & Fig : 3).Mean uric acd value & standard 
 
 
deviation  for the study group are 8.1 & 0.56.Mean uric acid value and 
standard deviation for the control group is 4.8 & 1.03.the estimated P value 
using unpaired t test is <0.0001.so this statistically very significant.Both 
were  compared with various out comes. 
CLINICAL STATUS- KILLIP CLASS & URIC ACID: 
In this study 32 patients presented with Killip class I, 24 patients 
presented with Killip class II, 28 patients presented with Killip class III, 16 
patients presented with Killip class IV. Killip class III & IV were taken as 
high risk category in this study and evaluated whether high uric acid 
concentration after myocardial infarction correlated with this high risk  
Killip class. 
When clinical status of patients based on killip class I to IV and   uric 
acid were analysed, the following observations were made.  In the control 
group who had normal serum uric acid level, 81.8 % belonged to I & II 
Killip class and only 18.2 % belonged to Killip class III & IV as against the 
study group 35.7  % Killip class I & II and 64.3 % Killip class III & IV 
which parallely associates with the elevated uric acid level and the clinical 
status (Table 6& 7,fig 5 &6 ). 
Our study correlates with kojima S, Sakamoto et al., (American 
journal of cardiology, 2005 Aug 15) who also showed patients who had high 
 
 
uric acid level belonged to higher Killip class. Hence uric acid can  also be 
used as an predictor of prognosis, but also a predictor of severity.Moreover 
incidence of killip class III & IV  in cases with concurrent 
hyperuricemia,hyperglycemia & dyslipidemia  is 72.3 % compared with 64.3 
% with study group ,so that concurrent elevation of uric acid,sugar & 
cholesterol significantly increases morbidity. 
TYPE OF INFARCTION & URIC ACID : 
In this study 32 patients presented with Anterior Wall Myocardial 
Infarction (AWMI) of which 18 patients had high uric acid level, 22 patients 
presented with Ext AWMI , of  which 12 patients had high uric acid level,22 
presented with mulitplewall MI,of which 13 patients had high uric acid level, 
14 patients presented with  Inferior Wall Myocardial Infarction (IWMI), of 
which 9 patients had high uric acid level , 8 patients presented with inferior 
and Right Ventricular Myocardial Infarction (RVMI), of which 4 patients 
had high uric acid level.  When areas of infarction and uric acid levels were 
observed, an increased level of uric acid in Anterior wall Myocardial 
Infarction was noted. This cannot be taken into statistical account, because 
the overall incidence of Anterior Wall Myocardial Infarction itself was high. 
(Table 10  & FIGURE 8 ). 
  
 
 
HEART FAILURE :  
44 out of 100 patients in this study had Heart failure in the post 
Myocardial Infarction period. So the incidence of heart failure was 44 %. Of 
which 26 (59  %) were males, 18 (41 %) were females.(Table 11 & 12, Fig 
9&10). It was observed that among 44 Heart failure patients, 36 patients had 
high uric acid level and 8 patients had normal uric acid level, 28 cases had 
concurrent high uric acid,sugar & cholesterol levels. So patients who had 
high uric acid level and normal uric acid level contributed to 82 %and 18 % 
respectively to Heart failure. (Table 10, Fig. 10) 
It was also found that 36 patients out of 56 patients with high uric acid 
level had Heart failure amounting to an incidence of 64.2 % Heart failure in 
this group. While only 8 out of 44 patients with normal uric acid level had 
Heart failure. ie. Only 18.1 % of patients with normal uric acid level had 
Heart failure. (Table 13,14,15,16 & 17 & fig 11,12,13, 14 & 15 ). 
The above figures suggest that the occurrence of Heart failure is high 
in patients with high uric acid level.  Moreover incidence of heart failure in 
cases with concurrent elevation of uric acid, sugar, cholesterol is 77.8 
%.concurrent elevation of serum uric acid along with blood sugar & total 
cholesterol predicts short term outcome. Our studies comparable with other 
studies who showed similar findings and elevated serum uric acid level is an 
early predictor of short term outcome. Kojima S. Sakamoto et al, (American 
 
 
journal of cardiology 2005 Aug 15) Anker SD, Doehner W et.al., ( 
Circulation 2003, Apr 22; circulation 2003 Nov 25) Sakai H, Tsutamoto T 
et. al.,(J cardiol.2006 May), Joshua M, Hare MD et.al., (circulation 2003, 
American Heart association), Virendra singh, RK Goyal et.al., ( Journal of 
the Indian Medical association 1977 Sep 1) studies support this study. Their 
studies revealed that serum uric acid level reflects circulatory xanthine 
oxidase activity and oxidative stress production. Increased serum uric acid 
level along with sugar & cholesterol  has been identified in patients who 
have congestive cardiac failure and is a marker of poor prognosis in such 
patients. 
ECHOCARDIOGRAM: 
In high uric acid population, 4 patients had normal LV function, 8 
patients had mild LV dysfunction, 26 patients had moderate LV dysfunction, 
18   patients had severe LV dysfunction. In normal uric acid level 
population, 28 patients had normal LV function, 7 patients had mild LV 
dysfunction, 6  patients had moderate LV dysfunction, 3 patients had severe 
LV dysfunction. (Table 18, Fig 16). So serum uric acid level can also be 
associated with Echocardiographic cardiac dysfunction later, retrospectively 
with clinical findings earlier. 
So uric acid level can be used as a definite predictor of cardiac failure. 
 
 
ARRHYTHMIAS : 
12  out of 100 patients developed Arrhythmias in this study. So the 
incidence of Arrhythmias was  12 % of which 5 (41.7 %) were males, 7  
(58.3 %) was female. 4 patients had ventricular tachycardia and 6 patients 
had heart block & 2 had supraventricular tachycardia (Table 19 & 20, Fig 
17&18 ). 
It was observed that among 12 Arrhythmias 9 patients had high uric 
level and 3 patients had normal uric acid level. So patients who had high uric 
acid level and normal uric acid level contributed to 75 % and 25 % 
respectively to Arrhythmias (Table 21 , Fig 19) . 
It was also found that 9  patients out of 56 patients with high uric acid 
level had  Arrhythmias amounting to an incidence of 16 % Arrhythmias in 
this group. While only 3  out of 44  patients with normal uric acid level had 
Arrhythmias. ie.only 6.8  % of patients with normal uric acid level had 
Arrhythmias. (Table  22&23,  Fig 20 & 21). 
The above findings suggest that the occurrence of Arrhythmias is also 
high in patients with high uric acid level. This observation can be matched 
with the outcome of a large randomized double blind placebo control clinical 
trial “Oxypurinol therapy for CHF” conducted in 2003, which could 
establish a beneficial effect for oxypurinol in reducing the incidence of 
 
 
Arrhythmias and other adverse cardiac events by lowering serum uric acid 
level. The above trial & our trial tells there is a high incidence of 
Arrhythmias when there is an elevated serum uric acid level and it is 
hypothetical an increased uric acid level may be arrhythmogenic. Further 
studies are needed to conclude. 
MORTALITY : 
15 out of 100 patients died due to their cardiac ailments in this study. 
This amounts to mortality rate of 15% of which 8 ( 53.3%) were males, 7 
(46.7 %) was female. (Table 24&25, Fig 22&23). To find out the prognostic 
significance of elevated uric acid level following Acute Myocardial 
Infarction, mortality rate in patients with normal and high uric acid level 
were separately calculated. It was observed that among 15 deaths 12 deaths 
were contributed by patients with high uric acid levels and 3 deaths by those 
who had normal uric acid levels. Thus 80% of death in post infarction period 
occurred in those who had a high uric acid level and only 20% in those who 
had a normal uric acid level. (Table 26 &  Fig 24) 
It was also found that 12 out of 56 patients with high uric acid level 
died. This implies a mortality rate of 21.4 %.Like wise a mortality rate of 6.8 
% was observed for patients with normal uric acid level following  
MyocardiaI Infarction (Table 27, Fig 25). This striking difference in the 
mortality figures for both group of patients implies uric acid level can be 
 
 
used as a predictor of mortality  following Myocardial Infarction. Out of 15 
deaths, 2 patients in the age group of 31-40 years,1  patients  were in the age 
group of 41-50 years, 7 patients  were in the age group of 51-60 years, 3  
patients  were in the age group of 61-70 years, 2 patients was in the >70 
years. (Table 28, Fig 26 ) 
Kojima S, Sakamoto et. al.,(American journal of cardiology 2005 Aug 
15) Fang J, Alderman M H et. al., (Serum uric acid and cardiovascular 
mortality, JAMA 2000) Bengtsson C, Lapidus L et.al., (Acta Med Scand 
1998) Freedman DS, Williamson DF et.al., (Relation of serum uric acid to 
mortality and Ischemic Heart disease Am. J. Epidemiol 1995) Culleton BF, 
Lassonmia et.al ., ( Serum uric acid and risk of cardiovascular disease and 
death Ann. Intern. Med July 6. 1999) studies supports this study. This study 
revealed that patients who developed short term adverse events like mortality 
following Myocardial Infarction had high uric acid concentrations. Our study 
also parallels with previous authors and uric acid can be used as a good 
predictor of mortality. 
ATYPICAL PRESENTATION : 
In the study only  46 patients presented with classical anginal  pain. So 
atypical presentation of myocardial infarction were more common in type 2 
diabetes ( table 29 & 27 ). 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
  
 
 
CONCLUSION 
1. Measuring serum Uric acid level  along with sugar & cholesterol is 
one of the predictable prognostic indicators in Acute Myocardial 
Infarction and one of the early and short term predictor. 
2. A high serum Uric acid level associated with short term mortality in 
Acute Myocardial Infarction. 
3. .Atypical presentation in myocardial infarction  were much more 
common in diabetic patients.  
4. Elevated serum Uric acid is strongly associated with cardiac 
Arrhythmias as against controls and can be used as an immediate 
prognostic indicator in Acute Myocardial Infarction. 
5. Elevated serum Uric acid level may be Arrhythmogenic. Further 
studies require to confirm and to treat. 
6. There is a strong association of elevated serum Uric acid and cardiac 
failure. 
7. Patients with high Uric acid level belonged to higher Killip class 
status (III & IV) . 
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Appendix 
 
 
 
 
 
 
ABBREVIATIONS 
 
MI  - MYOCARDIAL  INFARCTION 
IHD - ISCHEMIC HEART DISEASE 
DM - DIABETES  MELLITUS 
UA - URIC ACID 
TC - TOTL CHOLESTEROL 
RBS - RANDOM BLOOD SUGAR 
HDL - HIGH  DENSITY LIPOPROTEIN 
LDL - LOW DENSITY  LIPOPROTEIN 
SD - STANDARD  DEVIATION 
STEMI - ST ELEVATION MYOCARDIAL INFARCTION 
CK-MB - CREATINE KINASE MB 
HF - HEART FAILURE 
BNP -  BRAIN NATRIURITIC PEPTIDE 
  
 
 
ANNEXURE 
CERTIFICATE OF CONSENT 
               I  have been invited to participate in research on “Metabolic factors 
and their impact on prognosis and early complications of acute myocardial 
infarction in type 2 diabetes mellitus ( serum uric acid , blood sugar & total 
cholesterol)”. I understand that it will involve answering a detailed 
questionnaire, undergoing a thorough physical exam, giving blood  samples 
.I have been informed that the risks are minimal and may include only slight 
pain and redness at sight of needle prick. I am aware that there may be no 
benefit to me personally and that I will not be compensated monetarily. I 
have been provided with the name of a researcher who can be easily 
contacted using the number and address I was given for that person.. I have 
had the opportunity to ask questions about it and any questions I have asked 
have been answered to my satisfaction. I consent voluntarily to participate as 
a participant in this research and understand that I have the right to withdraw 
from the research at anytime without in anyway affecting my medical care. 
 
 
Name of the participant : ____________________ 
Signature of the participant : ____________________ 
Date : ____________________ 
 
If  illiterate,  a  witness must sign ( if possible, this  person  should  be  
selected  by  the participant  and  must have no connection to the research 
team). 
 
 
 
I  have  witnessed  the accurate reading  of  the consent form to the 
potential  participant, translated  to his/ her  mother tongue ,   and  the 
individual  has  had opportunity to ask questions. I confirm that the 
individual has given the consent freely. 
 
 
Name of witness :       _______________________  AND        Thumb print of participant 
Signature of witness :  _______________________ 
Date  : _______________________ 
    
 
 
(Day/Month/Year) 
           
I have  accurately read or witnessed the accurate reading  of  the  
consent form to the  potential  participant, I  confirm that the  individual has 
given the consent freely. 
 
Name  of  the  researcher : 
Signature of the researcher  with  date : 
 
 
 
 
 
  
 
 
PROFORMA 
 
NAME :                   AGE :          SEX:        OCCUPATION :           I.P.NO: 
ADDRESS :             D.O.A :                       D.O.D : 
SYMPTOMS AT THE TIME OF ADMISSION: 
CHEST PAIN, DYSPNOEA, SWEATING, PALPITATIONS 
OLIGURIA PAIN & SWELLING IN JOINTS 
PAST HISTORY : 
RENAL DISEASE GOUT CHRONIC ALCOHOLISM 
IHD  DIABETES ASPIRIN & DIURETIC THERAPHY 
ECG : 
KILLIP’S CLASSIFICATION : I II III IV 
THROMBOLYSED : NOT THROMBOLYSED : 
CLINICAL EXAMINATION :  
a. PR : 
b. BP : 
c. JVP elevation : Yes / No 
d. Pedal edema : Yes / No 
e. Basal Rales : Yes / No 
INVESTIGATIONS : 
a. Hb % : b. TC : c. DC :                   d. URINE : ALB : SUGAR : DEPOSITS : 
e. BLOOD SUGAR :                           f. BLOOD UREA: 
g. SERUM CREATININE :                h. SERUM ELECTROLYTES : Na+ : K+ : 
i. SERUM URIC ACID LEVEL ON ADMISSION :   j. SERUM CHOLESTEROL k. 
ECHOCARDIOGRAM : 
ADVERSE CARDIAC EVENTS: 
a. CARDIAC FAILURE :                     b. ARRHYTHMIAS 
c. SHOCK                                            d. DEATH                           f . HOSPITAL STAY  
 
 
 
MASTER CHART 
S.No AGE SEX ANGINA VOMITIN GIDDINES DKA CVA LVF 
URIC 
ACID 
GLUCOSE CHOLEST AWMI EX AWMI 
MUL  
MI 
IWMI IW+RWMI 
KIL 
 I & II 
KIL III 
&IV 
HF ECHO ARRTHY DEATH 
1 43 F Y N N N N N 8.1 268 205 N N Y N N Y N N MILD N N 
2 65 F N Y N N N Y 9.1 356 321 N Y N N N N Y Y SEVERE Y Y 
3 57 M Y N N N N Y 9.2 288 268 Y N N N N N Y Y MODERAT N N 
4 71 M N N N Y N Y 9.2 546 344 N Y N N N N Y Y SEVERE N Y 
5 68 F N N N N N Y 7.6 168 222 Y N N N N N Y Y MODERAT N N 
6 51 M Y N N N N N 8.1 198 168  N  Y N N N N Y Y MODERAT N N 
7 59 F Y N N N N Y 7.6 326 286 Y N N N N N Y Y SEVERE N Y 
8 46 M N N N Y N N 6.2 586 166 N N Y N N Y N N NORMAL N N 
9 52 F Y N N N N N 9.1 156 178 N N N Y N N Y Y MODERAT N N 
10 49 M N N Y N N N 7.4 174 194 Y N N N N Y N N NORMAL N N 
11 59 F N N Y N N N 7.2 302 336 N N N Y N Y N N NORMAL N N 
12 35 F Y N N Y N N 5.4 504 268 Y N N N N Y N N  MILD N N 
13 55 F N N N N Y Y 7.5 348 294 N N Y N N N Y Y MODERAT N N 
14 47 F Y N N N N N 6.7 186 178 N N N Y N Y N N NORMAL N N 
15 67 F N N N N N Y 7.4 262 284 Y N N N N N Y Y SEVERE N N 
16 49 M N N N Y N N 7.4 588 234 N Y N N N Y N N NORMAL N N 
17 52 M Y N N N N Y 7.5 322 348 N N N Y N N Y Y MODERAT N N 
18 37 M Y N N N N Y 7.2 189 162 Y N N N N N Y Y MODERAT N N 
19 45 F N Y N N N N 7.5 268 205 N N Y N N Y N N MILD N N 
20 48 M Y N N N N Y 7.4 286 302 Y N N N N N Y Y SEVERE N N 
21 64 M N N N Y N Y 5.6 542 198 N Y N N N Y N N MILD N N 
22 69 F N N N N N Y 8.2 265 256 Y N N N N N Y Y MODERAT N N 
23 47 M Y N N N N Y 4.5 283 184 N N N Y N N Y Y MODERAT N N 
24 35 M N N N Y N N 3.6 604 173 N Y N N N Y N N NORMAL N N 
 
 
25 59 F N N Y N N Y 7.6 296 316 N Y N N N N Y Y MODERAT N N 
26 46 M Y N N N N Y 6.6 164 196 N N N Y N Y N N SEVERE Y Y 
27 36 M N N N Y N N 5.4 508 168 Y N N N N Y N N NORMAL N N 
28 55 F N N Y N N N 7.7 174 174 N N Y N N Y N N MODERAT N N 
29 51 F Y N Y N N Y 7.5 292 306 N Y N N N N Y Y MODERAT N N 
30 33 M N N Y N N N 8.2 364 282 Y N N N N Y N N MILD N N 
31 53 F Y N N N N N 7.5 169 194 Y N N N N Y N N NORMAL N N 
32 49 F N N N N N Y 8.4 308 356 N N N Y N N Y Y MODERAT Y N 
33 59 M N N N N N Y 6.2 184 168 Y N N N N N Y Y SEVERE N N 
34 58 M Y N N N N Y 8.5 194 158 N N Y N N N Y Y MODERAT N N 
35 48 F Y N N N N Y 8.5 268 288 N N N Y N N Y Y MODERAT N N 
36 47 M N N Y N N N 7.2 163 169 Y N N N N Y N N MILD N N 
37 51 M Y N N N N Y 8.3 298 308 N Y N N N N Y Y MODERAT N N 
38 64 F N N Y N N N 4.3 178 176 N N N Y N Y N N NORMAL N N 
39 35 M N Y N N N Y 9.4 308 366 Y N N N N N Y Y SEVERE N Y 
40 45 M Y N N N N Y 4.4 163 169 N N N N Y N Y Y MODERAT N N 
41 53 F N N Y N N N 5.6 198 159 Y N N N N Y N N MILD N N 
42 59 M N N Y N N Y 9.4 568 368 N N Y N N N Y Y SEVERE N Y 
43 36 F Y N N N N N 3.5 333 168 Y N N N N Y N N NORMAL N N 
44 49 F N N N N N Y 8.2 346 268 Y N N N N N Y Y MODERAT N N 
45 55 F N Y N N N N 5.6 205 194 N N N Y N Y N N SEVERE Y Y 
46 45 M Y N N N N N 3.4 207 176 Y N N N N Y N N NORMAL N N 
47 69 F Y N N N N Y 8.4 404 346 N N N N Y N Y Y SEVERE N Y 
48 37 M N N Y N N Y 6.2 208 184 N N Y N N N Y Y MODERAT N N 
49 53 M Y N N N N N 8.1 243 300 Y N N N N Y N N NORMAL N N 
50 48 M Y N N N N Y 3.4 248 148 N N N N N N Y Y MODERAT N N 
 
 
51 57 M N N N Y N Y 3.4 608 158 Y N N N N N Y Y SEVERE N N 
52 52 F Y N N N N N 7.4 295 274 N N N N Y Y N N MILD N N 
53 47 M N N Y N N N 5.5 236 194 N Y N N N Y N N NORMAL N N 
54 36 F N N N Y N N 4.4 642 186 N N Y N N Y N N NORMAL N N 
55 63 F N N N N N Y 8.1 306 268 Y N N N N N Y Y SEVERE N Y 
56 48 M Y N N N N N 6.4 222 176 N N Y N N Y N N MILD N N 
57 48 M N N Y N N N 4.5 158 184 Y N N N N Y N N NORMAL N N 
58 37 M Y N N N N Y 8.4 356 283 N N N Y N N Y Y SEVERE Y Y 
59 52 F N N Y N N N 3.4 184 182 Y N N N N Y N N NORMAL N N 
60 48 F Y N N N N Y 7.8 289 322 N N N N Y N Y Y MODERAT N N 
61 51 M N Y N N N N 5.6 228 195 Y N N N N Y N N NORMAL N N 
62 57 M N N N N N Y 8.2 226 268 N N Y N N N Y Y MODERAT N N 
63 63 M Y N N N N N 4.3 137 168 N Y N N N Y N N NORMAL N N 
64 52 F N Y N N N Y 9.2 394 308 N Y N N N N Y Y SEVERE N Y 
65 58 M Y N N N N N 5.4 194 148 N N N Y N Y N N NORMAL N N 
66 55 F N N Y N N N 5.5 138 171 Y N N N N Y N N NORMAL N N 
67 52 M N N N Y N N 7.3 567 268 N N N N Y Y N N MILD N N 
68 46 M Y N N N N N 5.3 111 186 N Y N N N Y N N NORMAL N N 
69 39 M N N Y N N Y 8.2 463 258 N Y N N N Y N N MODERAT N N 
70 52 F Y N N N N N 3.3 92 179 N N Y N N Y N N NORMAL N N 
71 48 F N N Y N N N 8.4 168 196 Y N N N N N Y Y MODERAT N N 
72 58 M Y N N N N N 5.4 308 268 N N Y N N N Y Y MODERAT N N 
73 77 M N N Y N N Y 5.6 242 194 Y N N N N N Y Y SEVERE Y Y 
74 49 F N N Y N N N 3.5 168 196 N N N N Y Y N N NORMAL N  N 
75 58 M N N N Y N Y 8.6 587 304 N Y N N N N Y Y MODERAT N N 
76 59 M N Y N N N N 4.8 164 182 Y N N N N Y N N NORMAL N N 
 
 
77 61 F Y N N N N Y 8.2 284 249 N N Y N N N Y Y MODERAT Y N 
78 44 M N N Y N N N 6.5 188 174 N Y N N N Y N N NORMAL N N 
79 52 M N Y N N N N 8.2 194 159 N N N Y N Y N N MODERAT N N 
80 53 M Y N N N N Y 9.1 308 266 Y N N N N N Y Y SEVERE Y Y 
81 44 F N N N Y N N 5.6 642 148 N N N N Y Y N N MILD N N 
82 48 M N N Y N N N 6.3 194 183 N N Y N N Y N N SEVERE N N 
83 73 F Y N N N N N 8.1 158 159 N N Y N N Y N N MILD N N 
84 59 M N N N N Y Y 9.2 542 298 N N Y N N N Y Y SEVERE Y Y 
85 57 M Y N N N N N 6.3 158 158 N Y N N N Y N N NORMAL N N 
86 44 F Y N N N N N 8.5 128 184 N N Y N N Y N N MILD N N 
87 49 M N N Y N N N 6.3 148 169 N N Y N N Y N N NORMAL N N 
88 58 F Y N N N N N 8.1 186 183 N N Y N N Y N N MODERAT Y N 
89 69 M N N Y N N N 5.2 348 266 Y N N N N Y N N NORMAL N N 
90 51 F Y N N N N Y 7.2 393 308 N Y N N N N Y Y SEVERE Y Y 
91 59 M N Y N N N N 4.8 186 206 N N N N Y Y N N NORMAL N N 
92 42 F Y N N N N N 4.6 226 205 N Y N N N Y N N MILD N N 
93 47 F N N Y N N Y 9.2 228 258 N N Y N N N Y Y MODERAT N N 
94 53 M Y N N N N N 6.3 158 228 N Y N N N Y N N NORMAL N N 
95 63 F Y N N N N Y 7.4 246 286 Y N N N N N Y Y SEVERE Y N 
96 57 F Y N N N N N 5.3 246 284 N N Y N N Y N N MODERAT N N 
97 47 M N Y N N N N 7.2 158 268 N N N Y N Y N N MODERAT N N 
98 48 F Y N N N N N 5.3 126 262 N N N N Y Y N N NORMAL N N 
99 64 F Y N N N N N 6.7 184 198 N Y N N N Y N N NORMAL N N 
100 36 M Y N N N N Y 5.6 186 198 N Y N N N Y N N MILD N N 
 
